Since then, PGE2 control of both beta-cell function and mass has been extensively studied and its receptor EP3 is a potential drug target for treatment of diabetes (recently reviewed by Carboneau et al. [23]). The gene discussed is PTGER3; the disease is diabetes mellitus.